Biologics Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global biologics market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorders, and hematological disorders. The global biologics market is expected to grow with a CAGR of XX% from 2020 to 2025. The major drivers for this market are rising biologics contract manufacturing services and recent advancements in biological science.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biologics market report, please download the report brochure.
In this market, monoclonal antibodies is the largest product type of biologics, whereas microbial is the largest source. Growth in various segments of the biologics market are given below:
The study includes trends and forecast for the global biologics market by product, source, disease category, manufacturing, distribution channel, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Monoclonal Antibodies (mABs)VaccinesRecombinant ProteinsAntisense, RNAi, & Molecular TherapyOthers
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
MicrobialMammalianOthers
By Disease Category [Value ($ Million) shipment analysis for 2014 – 2025]:
OncologyImmunological DisorderCardiovascular DisordersHematological DisordersOthers
By Manufacturing [Value ($ Million) shipment analysis for 2014 – 2025]:
OutsourcedIn-house
By Distribution Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
OnlineOffline
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the WorldBrazil
Some of the biologics companies profiled in this report include Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, Abbvie, Sanofi, Pfizer, and Merck & Co.
Lucintel forecasts that the monoclonal antibodies (mABs) will remain the largest segment over the forecast period due to its increasing usage in different therapeutic areas such as cancer management, treatment of autoimmune diseases, including rheumatoid arthritis.
Within this market, microbial will remain the largest segment by source over the forecast period due to increasing number of drugs generated by using microbial system such as recombinant insulin, platelet-derived growth factor, granulocyte-macrophage colony-stimulating factor, and recombinant interferon.
North America will remain the largest region over the forecast period due to increasing R&D activities in biotechnology and presence of significant participants in this region.
Features of the Global Biologics Market
Market Size Estimates: Global biologics market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biologics market size by various segments, such as by product, source, disease category, manufacturing, and distribution channel in terms of value.Regional Analysis: Global biologics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different by product, source, disease category, manufacturing, distribution channel, and region for the global biologics market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biologics market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biologics market by product (monoclonal antibodies (mABs), vaccines, recombinant proteins, antisense, RNAi, & molecular therapy, and others), source (microbial, mammalian, and others), disease category (oncology, immunological disorder, cardiovascular disorders, hematological disorders, and others), manufacturing (outsourced and in-house), distribution channel (online and offline), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biologics market?
Q.5 What are the business risks and threats to the global biologics market?
Q.6 What are the emerging trends in this biologics market and the reasons behind them?
Q.7 What are some changing demands of customers in this biologics market?
Q.8 What are the new developments in this biologics market? Which companies are leading these developments?
Q.9 Who are the major players in this biologics market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biologics market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biologics market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others), Source (Microbial, Mammalian, and Others), Disease Category (Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others), Manufacturing (Outsourced and In-house), and Distribution Channel (Online, and Offline)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global biologics market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorders, and hematological disorders. The global biologics market is expected to grow with a CAGR of XX% from 2020 to 2025. The major drivers for this market are rising biologics contract manufacturing services and recent advancements in biological science.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biologics market report, please download the report brochure.
In this market, monoclonal antibodies is the largest product type of biologics, whereas microbial is the largest source. Growth in various segments of the biologics market are given below:
The study includes trends and forecast for the global biologics market by product, source, disease category, manufacturing, distribution channel, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Monoclonal Antibodies (mABs)VaccinesRecombinant ProteinsAntisense, RNAi, & Molecular TherapyOthers
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
MicrobialMammalianOthers
By Disease Category [Value ($ Million) shipment analysis for 2014 – 2025]:
OncologyImmunological DisorderCardiovascular DisordersHematological DisordersOthers
By Manufacturing [Value ($ Million) shipment analysis for 2014 – 2025]:
OutsourcedIn-house
By Distribution Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
OnlineOffline
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the WorldBrazil
Some of the biologics companies profiled in this report include Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, Abbvie, Sanofi, Pfizer, and Merck & Co.
Lucintel forecasts that the monoclonal antibodies (mABs) will remain the largest segment over the forecast period due to its increasing usage in different therapeutic areas such as cancer management, treatment of autoimmune diseases, including rheumatoid arthritis.
Within this market, microbial will remain the largest segment by source over the forecast period due to increasing number of drugs generated by using microbial system such as recombinant insulin, platelet-derived growth factor, granulocyte-macrophage colony-stimulating factor, and recombinant interferon.
North America will remain the largest region over the forecast period due to increasing R&D activities in biotechnology and presence of significant participants in this region.
Features of the Global Biologics Market
Market Size Estimates: Global biologics market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biologics market size by various segments, such as by product, source, disease category, manufacturing, and distribution channel in terms of value.Regional Analysis: Global biologics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different by product, source, disease category, manufacturing, distribution channel, and region for the global biologics market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biologics market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biologics market by product (monoclonal antibodies (mABs), vaccines, recombinant proteins, antisense, RNAi, & molecular therapy, and others), source (microbial, mammalian, and others), disease category (oncology, immunological disorder, cardiovascular disorders, hematological disorders, and others), manufacturing (outsourced and in-house), distribution channel (online and offline), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biologics market?
Q.5 What are the business risks and threats to the global biologics market?
Q.6 What are the emerging trends in this biologics market and the reasons behind them?
Q.7 What are some changing demands of customers in this biologics market?
Q.8 What are the new developments in this biologics market? Which companies are leading these developments?
Q.9 Who are the major players in this biologics market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biologics market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biologics market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others), Source (Microbial, Mammalian, and Others), Disease Category (Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others), Manufacturing (Outsourced and In-house), and Distribution Channel (Online, and Offline)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biologics Market Trends and Forecast
3.3: Global Biologics Market by Product
3.3.1: Monoclonal Antibodies (mABs)
3.3.2: Vaccines
3.3.3: Recombinant Proteins
3.3.4: Antisense, RNAi, & Molecular Therapy
3.3.5: Others
3.4. Global Biologics Market by Source
3.4.1: Microbial
3.4.2: Mammalian
3.4.3: Others
3.5. Global Biologics Market by Disease Category
3.5.1: Oncology
3.5.2: Immunological Disorder
3.5.3: Cardiovascular Disorders
3.5.4: Hematological Disorders
3.5.5: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biologics Market by Region
4.2: North American Biologics Market
4.2.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.2.2: Market by Source: Microbial, Mammalian, and Others
4.2.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.2.4: Market by Manufacturing: Outsourced and In-house
4.2.5: Market by Distribution Channel: Online and Offline
4.2.6: The United States Biologics Market
4.2.7: The Canadian Biologics Market
4.2.8: The Mexican Biologics Market
4.3. European Biologics Market
4.3.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.3.2: Market by Source: Microbial, Mammalian, and Others
4.3.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.3.4: Market by Manufacturing: Outsourced and In-house
4.3.5: Market by Distribution Channel: Online and Offline
4.3.6: The Biologics Market of United Kingdom
4.3.7: The Spanish Biologics Market
4.3.8: The German Biologics Market
4.3.9: The French Biologics Market
4.4. APAC Biologics Market
4.4.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.4.2:Market by Source: Microbial, Mammalian, and Others
4.4.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.4.4: Market by Manufacturing: Outsourced and In-house
4.4.5: Market by Distribution Channel: Online and Offline
4.4.6: The Chinese Biologics Market
4.4.7: The Indian Biologics Market
4.4.8: The Japanese Biologics Market
4.5. ROW Biologics Market
4.5.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.5.2: Market by Source: Microbial, Mammalian, and Others
4.5.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.5.4: Market by Manufacturing: Outsourced and In-house
4.5.5: Market by Distribution Channel: Online and Offline
4.5.6: Brazilian Biologics Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biologics Market by Product
7.1.2: Growth Opportunities for the Global Biologics Market by Source
7.1.3: Growth Opportunities for the Global Biologics Market by Disease Category
7.1.4: Growth Opportunities for the Global Biologics Market by Manufacturing
7.1.5: Growth Opportunities for the Global Biologics Market by Distribution Channel
7.1.6: Growth Opportunities for the Global Biologics Market by Region
7.2: Emerging Trends in the Global Biologics Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biologics Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biologics Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Eli Lilly & Company
8.2: Samsung Biologics
8.3: F Hoffman La Roche.
8.4: Celltrion.
8.5: Addgene
8.6: Amgen
8.7: Abbvie Inc.
8.8: Sanofi
8.9: Pfizer Inc.
8.10: Merck & Co. Inc.
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biologics Market Trends and Forecast
3.3: Global Biologics Market by Product
3.3.1: Monoclonal Antibodies (mABs)
3.3.2: Vaccines
3.3.3: Recombinant Proteins
3.3.4: Antisense, RNAi, & Molecular Therapy
3.3.5: Others
3.4. Global Biologics Market by Source
3.4.1: Microbial
3.4.2: Mammalian
3.4.3: Others
3.5. Global Biologics Market by Disease Category
3.5.1: Oncology
3.5.2: Immunological Disorder
3.5.3: Cardiovascular Disorders
3.5.4: Hematological Disorders
3.5.5: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biologics Market by Region
4.2: North American Biologics Market
4.2.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.2.2: Market by Source: Microbial, Mammalian, and Others
4.2.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.2.4: Market by Manufacturing: Outsourced and In-house
4.2.5: Market by Distribution Channel: Online and Offline
4.2.6: The United States Biologics Market
4.2.7: The Canadian Biologics Market
4.2.8: The Mexican Biologics Market
4.3. European Biologics Market
4.3.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.3.2: Market by Source: Microbial, Mammalian, and Others
4.3.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.3.4: Market by Manufacturing: Outsourced and In-house
4.3.5: Market by Distribution Channel: Online and Offline
4.3.6: The Biologics Market of United Kingdom
4.3.7: The Spanish Biologics Market
4.3.8: The German Biologics Market
4.3.9: The French Biologics Market
4.4. APAC Biologics Market
4.4.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.4.2:Market by Source: Microbial, Mammalian, and Others
4.4.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.4.4: Market by Manufacturing: Outsourced and In-house
4.4.5: Market by Distribution Channel: Online and Offline
4.4.6: The Chinese Biologics Market
4.4.7: The Indian Biologics Market
4.4.8: The Japanese Biologics Market
4.5. ROW Biologics Market
4.5.1: Market by Product: Monoclonal Antibodies (mABs), Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others
4.5.2: Market by Source: Microbial, Mammalian, and Others
4.5.3: Market by Disease Category: Oncology, Immunological Disorder, Cardiovascular Disorders, Hematological Disorders, and Others
4.5.4: Market by Manufacturing: Outsourced and In-house
4.5.5: Market by Distribution Channel: Online and Offline
4.5.6: Brazilian Biologics Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biologics Market by Product
7.1.2: Growth Opportunities for the Global Biologics Market by Source
7.1.3: Growth Opportunities for the Global Biologics Market by Disease Category
7.1.4: Growth Opportunities for the Global Biologics Market by Manufacturing
7.1.5: Growth Opportunities for the Global Biologics Market by Distribution Channel
7.1.6: Growth Opportunities for the Global Biologics Market by Region
7.2: Emerging Trends in the Global Biologics Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biologics Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biologics Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Eli Lilly & Company
8.2: Samsung Biologics
8.3: F Hoffman La Roche.
8.4: Celltrion.
8.5: Addgene
8.6: Amgen
8.7: Abbvie Inc.
8.8: Sanofi
8.9: Pfizer Inc.
8.10: Merck & Co. Inc.
